Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Assets (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Assets readings, the most recent being $329.5 million for Q4 2025.

  • On a quarterly basis, Assets fell 5.49% to $329.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $329.5 million, a 5.49% decrease, with the full-year FY2025 number at $280.7 million, down 25.47% from a year prior.
  • Assets hit $329.5 million in Q4 2025 for Enanta Pharmaceuticals, up from $280.7 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $495.2 million in Q2 2023 to a low of $280.7 million in Q3 2025.
  • Median Assets over the past 5 years was $392.0 million (2022), compared with a mean of $389.8 million.
  • Biggest five-year swings in Assets: increased 28.54% in 2023 and later fell 25.47% in 2025.
  • Enanta Pharmaceuticals' Assets stood at $440.6 million in 2021, then fell by 21.12% to $347.5 million in 2022, then grew by 23.3% to $428.5 million in 2023, then fell by 18.64% to $348.6 million in 2024, then dropped by 5.49% to $329.5 million in 2025.
  • The last three reported values for Assets were $329.5 million (Q4 2025), $280.7 million (Q3 2025), and $301.0 million (Q2 2025) per Business Quant data.